Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Eniluracil by Processa Pharmaceuticals for Solid Tumor: Likelihood of Approval
Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Eniluracil by Processa Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval
Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
Eniluracil by Processa Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Eniluracil by Processa Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Eniluracil by Processa Pharmaceuticals for Metastatic Breast Cancer: Likelihood of Approval
Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...
Eniluracil by Processa Pharmaceuticals for Gastrointestinal Tumor: Likelihood of Approval
Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase I for Gastrointestinal Tumor. According to GlobalData, Phase...
Eniluracil by Processa Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval
Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...